Skip to main content

Advertisement

SpringerLink
Log in

The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) are prognostic factors for hepatocellular carcinoma (HCC). The impact of these tumor markers in recurrent HCC on the prognosis remains to be fully elucidated.

Methods

Two hundred and seventeen patients whose AFP and DCP levels were measured at recurrence were enrolled in the present study. AFP levels >10 ng/mL and DCP levels ≥40 mAU/mL were defined as AFP positive (AFP+) and DCP positive (DCP+), respectively. The patterns of tumor markers were scored as AFP−/DCP−, 0; AFP+/DCP− or AFP−/DCP+, 1 and AFP+/DCP+, 2.

Results

The median survival period after recurrence in patients with a score of 2 (26.6 months) was significantly lower than that in patients with scores of 1 or 0 (43.5 months, P < 0.01; 75.3 months, P < 0.01, respectively). A multivariate analysis showed that a tumor marker score of 2 at recurrence was an independent predictor for poor survival after recurrence (hazard ratio 2.12, P = 0.03). The prognosis after recurrence in the patients with a decreased tumor maker score was significantly better than that in the patients with no change in the tumor marker score compared to the primary surgery (P = 0.048).

Conclusions

The present study shows that measurements of both AFP and DCP are useful for predicting the prognosis of recurrent HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:212–36.

    Article  PubMed  Google Scholar 

  2. Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996;111:720–6.

    Article  CAS  PubMed  Google Scholar 

  3. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Kobayashi K, Ishiyama K, Ohdan H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today. 2013;43:1347–54.

    Article  CAS  PubMed  Google Scholar 

  5. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology. 1986;90:263–7.

    CAS  PubMed  Google Scholar 

  6. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19–26.

    Article  CAS  PubMed  Google Scholar 

  7. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427–31.

    Article  CAS  PubMed  Google Scholar 

  8. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol. 1987;4:357–63.

    Article  CAS  PubMed  Google Scholar 

  9. Shimada M, Takenaka K, Fujiwara Y, Gion T, Kajiyama K, Maeda T, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer. 1996;78:2094–100.

    Article  CAS  PubMed  Google Scholar 

  10. Nakao A, Taniguchi K, Inoue S, Harada A, Nonami T, Watanabe K, et al. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma. Semin Surg Oncol. 1996;12:160–3.

    Article  CAS  PubMed  Google Scholar 

  11. Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16:2795–804.

    Article  PubMed  Google Scholar 

  12. Kaibori M, Matsui Y, Yanagida H, Yokoigawa N, Kwon AH, Kamiyama Y. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma. World J Surg. 2004;28:702–7.

    Article  PubMed  Google Scholar 

  13. Hirohashi K, Shuto T, Kubo S, Tanaka H, Yamamoto T, Ikebe T, et al. Prognostic factors after recurrence of resected hepatocellular carcinoma associated with hepatitis C virus. J Hepatobiliary Pancreat Surg. 2001;8:81–6.

    Article  CAS  PubMed  Google Scholar 

  14. Sobin LH, Gospodarowicz MK, Wittekind CH, editors. TNM Classification of Malignant Tumours. 7th ed. New York: Wiley-Liss; 2009.

    Google Scholar 

  15. The Japan Society of Hepatology. Clinical Practice Guidelines for Hepatocellular Carcinoma 2013 (in Japanese). Tokyo: Kanehara and Co., Ltd; 2013.

    Google Scholar 

  16. Ohba T, Yano T, Yoshida T, Kawano D, Tsukamoto S, Shoji F, et al. Results of a surgical resection of pulmonary metastasis from hepatocellular carcinoma: prognostic impact of the preoperative serum alpha-fetoprotein level. Surg Today. 2012;42:526–31.

    Article  CAS  PubMed  Google Scholar 

  17. Tomimaru Y, Wada H, Eguchi H, Tomokuni A, Hama N, Kawamoto K, et al. Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma. Surg Today. 2014. doi:10.1007/s00595-014-1028-8.

    Google Scholar 

  18. Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis. 1986;6:259–66.

    Article  CAS  PubMed  Google Scholar 

  19. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998;27:1394–402.

    Article  CAS  PubMed  Google Scholar 

  20. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer. 1998;82:827–35.

    Article  CAS  PubMed  Google Scholar 

  21. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology. 1995;22:1027–33.

    Article  CAS  PubMed  Google Scholar 

  22. Miyagawa S, Kawasaki S, Makuuchi M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology. 1996;24:307–10.

    Article  CAS  PubMed  Google Scholar 

  23. Yamanaka N, Tanaka T, Tanaka W, Yamanaka J, Yasui C, Kuroda N, et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer. 1997;79:1509–15.

    Article  CAS  PubMed  Google Scholar 

  24. Wu CC, Ho WL, Chen JT, Tang JS, Yeh DC, P’eng FK. Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma. Br J Surg. 1999;86:1391–6.

    Article  CAS  PubMed  Google Scholar 

  25. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus–an analysis of 236 consecutive patients with a single lesion. Hepatology. 2000;32:1216–23.

    Article  CAS  PubMed  Google Scholar 

  26. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg. 2012;204:300–7.

    Article  PubMed  Google Scholar 

  27. Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Kaneoka Y, et al. Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol. 2012;57:1251–7.

    Article  CAS  PubMed  Google Scholar 

  28. Kiriyama S, Uchiyama K, Ueno M, Ozawa S, Hayami S, Tani M, et al. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival. Ann Surg. 2011;254:984–91.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, 1007, Shimo-Nagakubo, Sunto-Nagaizumi, Shizuoka, 411-8777, Japan

    Yukiyasu Okamura, Ryo Ashida, Takaaki Ito, Teiichi Sugiura & Katsuhiko Uesaka

  2. Clinical Trial Coordination Office Biostatistician, Shizuoka Cancer Center Hospital, 1007, Shimo-Nagakubo, Sunto-Nagaizumi, Shizuoka, 411-8777, Japan

    Keita Mori

Authors
  1. Yukiyasu Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryo Ashida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takaaki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teiichi Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keita Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katsuhiko Uesaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukiyasu Okamura.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okamura, Y., Ashida, R., Ito, T. et al. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma. Surg Today 45, 1513–1520 (2015). https://doi.org/10.1007/s00595-014-1102-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-014-1102-2

Keywords

Search

Navigation